1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters

Showing 1,267 results.

CT - 126

Does CAR-T Therapy Overcome TP53-Driven Resistance in Lymphoma? A Systematic Review of Clinical Outcomes

Mostafa F Mohammed Saleh

Poster Presenter: Mostafa F Mohammed Saleh

MM - 127

Association Between Statin Use and Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis

Caryn Louise Gutierrez

Poster Presenter: Caryn Louise Gutierrez

MPN - 129

Efficacy and Safety of Ropeginterferon in Myeloproliferative Neoplasms: A Systematic Review and Meta-Analysis

Mahmood Aldapt

Poster Presenter: Mahmood Aldapt

Thumbnail for Does Minimal Residual Disease Negativity Overcome High-Risk Cytogenetics After Autologous Stem Cell Transplantation in Multiple Myeloma?

MM - 130

Does Minimal Residual Disease Negativity Overcome High-Risk Cytogenetics After Autologous Stem Cell Transplantation in Multiple Myeloma?

Rithika Manjunatha Reddy

Poster Presenter: Rithika Manjunatha Reddy

Thumbnail for Immune Effector Cell (IEC)-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) in Patients With Hematologic Malignancies: A Systematic Review and Meta-Analysis

CT - 131

Immune Effector Cell (IEC)-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) in Patients With Hematologic Malignancies: A Systematic Review and Meta-Analysis

Motaz Almahmood

Poster Presenter: Motaz Almahmood

Thumbnail for Efficacy and Toxicity of FLAG-IDA-Venetoclax Compared With Other Induction Regimens in Newly Diagnosed and Relapsed AML: A Real-World Single-Center Study

AML - 132

Efficacy and Toxicity of FLAG-IDA-Venetoclax Compared With Other Induction Regimens in Newly Diagnosed and Relapsed AML: A Real-World Single-Center Study

Rita Ahmad

Poster Presenter: Rita Ahmad

$Thumbnail for Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis$

MM - 134

Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis

Meletios A Dimopoulos

Poster Presenter: Meletios A Dimopoulos

Thumbnail for Comparative Effectiveness of Standard 3+7 Versus FLAG/FLAG-IDA Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Propensity Score-Matched Cohort Study Using the TriNetX Global Network

AML - 138

Comparative Effectiveness of Standard 3+7 Versus FLAG/FLAG-IDA Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Propensity Score-Matched Cohort Study Using the TriNetX Global Network

Rita Ahmad

Poster Presenter: Rita Ahmad

$Thumbnail for Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma$

IBCL - 141

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma

Javier Munoz

Poster Presenter: Javier Munoz